Forest Laboratories, Inc. (FRX) Bets Up to $460 Million on Trevena, Inc. Heart Failure Drug
5/9/2013 7:05:10 AM
More...
|
Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference
4/22/2013 7:27:49 AM
More...
|
Trevena, Inc. to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130
3/18/2013 9:59:47 AM
More...
|
Trevena, Inc. to Present Results of TRV027 Phase 2a Study in Patients With Advanced Heart Failure
3/8/2013 8:50:38 AM
More...
|
Trevena, Inc.'s Maxine Gowen Named CEO of the Year by PA Bio
2/8/2013 10:22:05 AM
More...
|
Trevena, Inc. GPCR Platform Yields a Novel Mu-opioid Biased Ligand Analgesic With Side Effect Benefits
1/23/2013 9:34:24 AM
More...
|
Trevena, Inc. Completes First-in-Human Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain
11/14/2012 9:32:51 AM
More...
|
Trevena, Inc. Founder Wins Nobel Chemistry Prize
10/11/2012 9:55:56 AM
More...
|
Trevena, Inc. Completes Phase 2a Study of TRV027 in Patients With Advanced Heart Failure
10/8/2012 9:53:11 AM
More...
|
Trevena, Inc. Presents Phase 1 Clinical Data for TRV027, a ß-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting
9/7/2012 10:29:57 AM
More...
|
|